Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ty method

investments 188 5,612

Minority interest 463 3,912

Gain (loss) on investments in

equity securities (3) 775 12,788

Other (160) (525)

Investment income 14,870 16,219

Interest expense (1,655) (4,188)

Total other income (expenses) 14,481 33,818

Income (loss) before income taxes (1) 205,388 229,380

(Provision for) benefit from income

taxes (1) (60,117) (71,193)

Net income (loss) (1) $145,271 $158,187

Net income (loss) per share:

Basic $0.54 $0.60

Diluted (1,4) $0.52 $0.57

Weighted average shares outstanding:

Basic 267,276 263,476

Diluted (1,4) 285,208 279,924

(1) In accordance with the provisions of Financial Accounting Standards

Board, or FASB, Statement of Financial Accounting Standards No., or

FAS, 123R, "Share-Based Payment, an amendment of FASB Statement Nos.

123 and 95," we recorded pre-tax charges for stock-based compensation

expense and related tax benefits of:

Three Months Ended

March 31,

2008 2007

Cost of products and services sold $(6,514) $(5,896)

Selling, general and administrative


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/29/2015)... ... ... Nearly everyone has heard of the potential of stem cells to treat ... of these cells is teeth—baby teeth that come loose during childhood, wisdom teeth extracted ... room for braces. These potent stem cells exist in the dental pulp of ...
(Date:7/28/2015)... VILLAGE, Nev. , July 28, 2015  PDL ... ) today announced that the Company will release its ... June 30, 2015, on Wednesday, August 5, 2015, after ... and webcast that day at 4:30 p.m. Eastern Time ... to the call will be available via the webcast ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... , EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - ... treatment of multiple sclerosis (MS), today announced that the Company ... Award" at the 4th Annual Scrip Awards held in London, ... development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide ...
... http://www.myngle.com ), the global language platform, has just ... Europe Unlimited,s European Venture Summit,(EVS)